Gastroenterology Phase 3 Deal Benchmarks (2026)

Understanding Gastroenterology Deal Benchmarks at Phase 3

Phase 3 Gastroenterology licensing deals command a median upfront payment of $1.5B, with values ranging from $979M at the low end to $2.0B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the gastroenterology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $3.9B to $6.7B, with a median of $5.3B. Royalty rates for gastroenterology assets at this stage typically fall between 10.7% and 19.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.